ANTIHYPERTENSIVE POLYOL COMPOUND AND DERIVATIVE THEREOF
申请人:East China University of Science and Technology
公开号:EP3906969A1
公开(公告)日:2021-11-10
The present invention provides a compound as represented by formula I, or a pharmaceutically acceptable salt or ester, a prodrug, an optical isomer, a stereoisomer, or a solvate thereof. The compound provided by the present invention can be used for preparing drugs for preventing or treating hypertension, or hypertension-related diseases, or pulmonary hypertension, or pulmonary hypertension-related diseases. The compound provided by the present invention has a different mechanism from existing drugs for treating hypertension and pulmonary hypertension, thereby laying a new material foundation for the development of drugs for treating hypertension and pulmonary hypertension.
Neue kristalline Salze von Aryloxy-propanolaminen, Verfahren zu ihrer Herstellung und ihre Verwendung
申请人:RORER INTERNATIONAL (OVERSEAS) INC.
公开号:EP0229947A1
公开(公告)日:1987-07-29
Die Erfindung betrifft neue kristalline Salze von Aryloxypropanolaminen mit Diphenylessigsäure, ein Verfahren zu deren Herstellung und die Verwendung dieser Salze zur Herstellung von chemisch reinen Aryloxypropanolaminen oder deren pharmazeutisch verträglichen Salzen.
The present invention provides a W/O/W multiple emulsion composition composed of an internal aqueous phase, an oil phase, and an external aqueous phase, the internal aqueous phase containing an ionic physiologically active substance and a physiologically acceptable compound having a molecular weight of 1,000 or less and generating a polyvalent counterion with two or more valencies for the ionic physiologically active substance. The W/O/W emulsion composition of the present invention not only can stably encapsulate a useful substance in its internal aqueous phase at a high encapsulation ratio, but also has high safety.
The present disclosure relates to a delivery device capable of delivering compositions. In some embodiments, the delivery device may deliver compositions to the gastrointestinal tract. In some embodiments, the compositions contain active drug substances. In some embodiments, the active drug substances are low permeable active drug substances.